GlassScriptPhysician profile
David J Mooney
NPI 1831350198
$120,228.11
in general payments reported to CMS, 2019-2025
92 companies · $46K in 2025
The $46K reported for 2025 was more than what 96% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,449 · 2020: $6,257 · 2021: $4,607 · 2022: $7,219 · 2023: $15K · 2024: $37K · 2025: $46K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $74K · Food and Beverage: $18K · Travel and Lodging: $5,808 · Education: $33.92 · Gift: $19.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $73,500.00 |
| Food and Beverage | $18,334.60 |
| Travel and Lodging | $5,807.86 |
| Education | $33.92 |
| Gift | $19.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Onmark, INC. | $86,510.03 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $2,746.08 | 2019-2025 | |
| Genentech USA, INC. | $2,628.21 | 2019-2024 | Polivy, Lunsumio, Columvi |
| E.R. Squibb & Sons, L.L.C. | $2,047.82 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Pfizer INC. | $2,003.08 | 2019-2025 | |
| Mckesson Specialty Care Distribution, LLC | $1,410.07 | 2019-2020 | |
| Janssen Biotech, INC. | $1,362.82 | 2019-2025 | Darzalex, Rybrevant, Talvey |
| US Oncology Corporate, INC. | $1,290.50 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $1,205.13 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Rigel Pharmaceuticals, INC. | $1,198.32 | 2019-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Astrazeneca Pharmaceuticals LP | $1,127.68 | 2019-2025 | Imfinzi, Calquence, Lynparza |
| Eisai INC. | $1,004.59 | 2019-2025 | |
| Celgene Corporation | $992.32 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Amgen INC. | $893.35 | 2019-2023 | Kyprolis, Blincyto |
| Takeda Pharmaceuticals U.S.A., INC. | $821.45 | 2019-2025 | Ninlaro, Fruzaqla, Iclusig |
Show all 91 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $722.47 | 2019-2025 | Enhertu, Datroway, Injectafer |
| Lilly USA, LLC | $703.07 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Incyte Corporation | $653.13 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Abbvie INC. | $622.55 | 2019-2025 | |
| Seagen INC. | $618.60 | 2019-2023 | Adcetris, Tukysa, Padcev |
| Genzyme Corporation | $613.71 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $548.76 | 2019-2025 | Ultomiris, Soliris |
| Octapharma USA, INC. | $528.07 | 2019-2021 | |
| Glaxosmithkline, LLC. | $379.33 | 2019-2025 | Jemperli, Ojjaara, Blenrep |
| Regeneron Healthcare Solutions, INC. | $372.94 | 2019-2025 | Libtayo, Lynozyfic |
| Gilead Sciences, INC. | $371.06 | 2019-2025 | Trodelvy |
| Bayer Healthcare Pharmaceuticals INC. | $366.63 | 2019-2025 | |
| Csl Behring | $361.34 | 2019-2023 | Hizentra |
| Beigene USA, INC. | $313.87 | 2020-2025 | Brukinsa, Tevimbra |
| Deciphera Pharmaceuticals INC. | $292.94 | 2022-2025 | Qinlock, Romvimza, Tgct |
| Ipsen Biopharmaceuticals, INC | $274.43 | 2019-2024 | Somatuline Depot, Onivyde |
| Stemline Therapeutics INC. | $266.43 | 2023-2025 | Orserdu |
| Pharmacyclics LLC, An Abbvie Company | $226.06 | 2020-2023 | Imbruvica |
| Karyopharm Therapeutics INC. | $208.92 | 2021-2025 | Xpovio |
| Exelixis INC. | $205.79 | 2019-2025 | Cabometyx |
| Puma Biotechnology, INC. | $201.83 | 2019-2025 | |
| Blueprint Medicines Corporation | $196.49 | 2020-2025 | Ayvakit |
| Sobi, INC | $186.20 | 2022-2025 | |
| Pharmacosmos Therapeutics INC. | $184.96 | 2021-2025 | Monoferric |
| Jazz Pharmaceuticals INC. | $182.04 | 2021-2024 | Zepzelca |
| Astellas Pharma US INC | $181.57 | 2020-2025 | Xtandi, Xospata |
| Kite Pharma, INC. | $176.66 | 2019-2025 | Yescarta |
| Myriad Genetic Laboratories, INC. | $173.95 | 2021-2024 | Myrisk, Precisetumor |
| Nuvasive, INC. | $170.56 | 2022 | |
| Array Biopharma INC | $159.54 | 2021-2025 | Braftovi, Lorbrena, Xalkori |
| Taiho Oncology, INC. | $144.32 | 2019-2024 | |
| Beone Medicines USA, INC. | $126.54 | 2025 | Brukinsa, Tevimbra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.73 | 2019-2025 | |
| Cti Biopharma Corp. | $119.20 | 2022-2023 | Vonjo |
| Global Blood Therapeutics, INC. | $117.70 | 2021-2022 | |
| Dova Pharmaceuticals | $112.13 | 2019-2021 | |
| Servier Pharmaceuticals LLC | $104.78 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $97.05 | 2023-2024 | Orgovyx |
| Epizyme, INC. | $93.83 | 2021-2022 | |
| Pharmaessentia USA Corporation | $92.00 | 2023-2025 | Besremi |
| Myovant Sciences INC. | $79.38 | 2021-2022 | |
| Adc Therapeutics America, INC. | $78.26 | 2022-2025 | |
| Tempus Ai, INC | $74.65 | 2024 | |
| Kyowa Kirin, INC. | $72.25 | 2019-2021 | |
| Emd Serono, INC. | $70.98 | 2019-2023 | Bavencio |
| Spectrum Pharmaceuticals INC. | $69.40 | 2023-2025 | Rolvedon |
| Acrotech Biopharma INC. | $66.40 | 2022-2023 | Beleodaq |
| Progenics Pharmaceuticals, INC. | $65.38 | 2022 | |
| Immunocore Limited | $59.94 | 2023-2025 | Kimmtrak |
| Janssen Pharmaceuticals, INC | $59.06 | 2019-2020 | |
| Mirati Therapeutics, INC. | $51.70 | 2023 | Krazati |
| Lexicon Pharmaceuticals, INC. | $47.01 | 2019-2020 | |
| Hema Biologics, LLC | $42.14 | 2023 | Sevenfact |
| Shield Therapeutics INC | $41.61 | 2023-2025 | Accrufer |
| Coherus Oncology, INC. | $41.02 | 2023-2025 | Loqtorzi |
| Morphosys, US INC. | $40.07 | 2022-2023 | Monjuvi |
| Aveo Pharmaceuticals, INC. | $39.15 | 2022 | |
| Verastem, INC. | $36.17 | 2019-2020 | |
| Apellis Pharmaceuticals, INC. | $35.34 | 2023-2024 | Empaveli |
| Helsinn Therapeutics (U.S.), INC. | $30.83 | 2019 | |
| Alnylam Pharmaceuticals INC. | $28.51 | 2025 | Givlaari |
| Amag Pharmaceuticals, INC. | $25.71 | 2021 | |
| Azurity Pharmaceuticals, INC. | $23.73 | 2025 | Danziten |
| Agios Pharmaceuticals, INC. | $23.49 | 2024 | Pyrukynd |
| Tersera Therapeutics LLC | $22.11 | 2022 | |
| Sun Pharmaceutical Industries INC. | $21.68 | 2025 | |
| Sanofi-Aventis U.S. LLC | $18.68 | 2021 | |
| Adaptive Biotechnologies Corporation | $18.38 | 2024 | Clonoseq |
| Springworks Therapeutics, INC. | $17.69 | 2025 | Ogsiveo |
| Shire North American Group INC | $17.09 | 2019 | |
| Genmab U.S., INC. | $16.45 | 2023 | Epkinly |
| Mylan Institutional INC. | $13.48 | 2022 | |
| Tesaro, INC. | $13.26 | 2019 | |
| Collegium Pharmaceutical, INC. | $11.57 | 2020 | |
| Clovis Oncology, INC. | $11.00 | 2019 | |
| Organon LLC | $6.91 | 2023 | Ontruzant |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Mooney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.